KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Interest Expenses (2018 - 2020)

Historic Interest Expenses for Xenon Pharmaceuticals (XENE) over the last 4 years, with Q2 2020 value amounting to $154000.0.

  • Xenon Pharmaceuticals' Interest Expenses fell 5780.82% to $154000.0 in Q2 2020 from the same period last year, while for Mar 2021 it was $154000.0, marking a year-over-year decrease of 8904.69%. This contributed to the annual value of $484000.0 for FY2020, which is 6624.83% down from last year.
  • According to the latest figures from Q2 2020, Xenon Pharmaceuticals' Interest Expenses is $154000.0, which was down 5780.82% from $330000.0 recorded in Q1 2020.
  • Over the past 5 years, Xenon Pharmaceuticals' Interest Expenses peaked at $678000.0 during Q3 2018, and registered a low of $154000.0 during Q2 2020.
  • Moreover, its 3-year median value for Interest Expenses was $348000.0 (2019), whereas its average is $328333.3.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Interest Expenses soared by 12515.72% in 2019, and later tumbled by 5780.82% in 2020.
  • Xenon Pharmaceuticals' Interest Expenses (Quarter) stood at $678000.0 in 2018, then crashed by 48.67% to $348000.0 in 2019, then plummeted by 55.75% to $154000.0 in 2020.
  • Its last three reported values are $154000.0 in Q2 2020, $330000.0 for Q1 2020, and $348000.0 during Q4 2019.